Patent details

EP2717902 Title: USE OF MODIFIED VASOACTIVE INTESTINAL PEPTIDES IN THE TREATMENT OF HYPERTENSION

Basic Information

Publication number:
EP2717902
PCT Application Number:
US2012041092
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP127963973
PCT Publication Number:
WO2012170524
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
USE OF MODIFIED VASOACTIVE INTESTINAL PEPTIDES IN THE TREATMENT OF HYPERTENSION
French Title of Invention:
UTILISATION DE PEPTIDES INTESTINAUX VASOACTIFS (PIV) MODIFIÉS POUR TRAITER L'HYPERTENSION
German Title of Invention:
VERWENDUNG MODIFIZIERTER VASOAKTIVER DARMPEPTIDE BEI DER BEHANDLUNG VON BLUTHOCHDRUCK
SPC Number:

Dates

Filing date:
06/06/2012
Grant date:
24/01/2018
EP Publication Date:
16/04/2014
PCT Publication Date:
13/12/2012
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
24/01/2018
EP B1 Publication Date:
24/01/2018
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
06/06/2018
Expiration date:
06/06/2032
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
17/01/2018
 
 

Name:
Phasebio Pharmaceuticals, Inc.
Address:
One Great Valley Parkway Suite 30, Malvern, Pennsylvania 19355, United States (US)

Inventor

1

Name:
GEORGOPOULOS, Lynne, M.
Address:
United States (US)

2

Name:
ARNOLD, Susan
Address:
United States (US)

Priority

Priority Number:
201161493845 P
Priority Date:
06/06/2011
Priority Country:
United States (US)

Classification

IPC classification:
A61K 38/17; A61P 31/10; C07K 14/47;

Publication

European Patent Bulletin

Issue number:
201804
Publication date:
24/01/2018
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
30/10/2018 Outgoing Correspondence 1